Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Sponsor
Tianjin Huanhu Hospital
Study ID
NCT07392528
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • QT-019C — DRUG
    Universal allogeneic anti-CD19/BCMA CAR T-cells

Study Details

This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells（QT-019C）.

Key Dates

First listed
Feb 6, 2026
Start date
Mar 31, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: QT-019C
    Universal allogeneic CD19/BCMA CAR T-cells

Primary Outcome Measure

The number and severity of dose-limiting toxicity (DLT) events [ Time Frame: Within 28 Days After QT-019C Infusion ]

Central Contacts

Find similar trials

Nationwide
Multiple sclerosis trialsNeurology trialsBrain disorders trialsAutoimmune disease trials

Related Studies